Latanoprost E Timololo Teva Italia (Timolol Maleate, Latanoprost)

Timolol blocks β‑adrenergic receptors in the ciliary body, reducing aqueous humor production, while latanoprost activates prostaglandin F2α receptors to increase uveoscleral outflow. Together they provide a dual mechanism that effectively lowers eye pressure.

The dosing regimen is determined by the prescribing ophthalmologist. Typically, one drop is instilled into the affected eye(s) once daily, but the exact frequency and duration depend on individual patient response and clinical judgment.

Safety data in pregnancy and lactation are limited. The product should be used only if the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made by the treating physician.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with single‑agent therapies, the timolol‑latanoprost combination offers complementary mechanisms—decreasing production and increasing outflow of aqueous humor—often achieving greater pressure reduction with a single daily drop, which can improve adherence versus multiple separate medications.

Store the bottle at room temperature, below 25 °C, in its original packaging. Keep the container tightly closed, protect it from light and moisture, and discard any solution that appears discolored or has been opened beyond the recommended period.

The product is applied topically as an eye drop. The patient should wash hands, tilt the head back, pull down the lower eyelid to create a pocket, and place one drop into the conjunctival sac. Close the eye gently and avoid blinking excessively for a few seconds.

Serious risks include severe allergic reactions (e.g., anaphylaxis), sudden loss of vision, acute eye pain, worsening glaucoma despite treatment, and systemic beta‑blocker effects such as bradycardia or bronchospasm, especially in patients with respiratory or cardiac conditions.

Patients with known hypersensitivity to timolol, latanoprost, or any excipients should avoid the product. It is also contraindicated in individuals with severe asthma, chronic obstructive pulmonary disease, sinus bradycardia, second‑ or third‑degree heart block, or those taking non‑selective systemic beta‑blockers without medical supervision.